TherapeuticsMD, Inc. (TXMD) stock
TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 12/3030% below fair value
$1.82−0.03 (-1.62%)
Close on Nov 12, 2026Market cap $21.07MP/E –Yield –
TherapeuticsMD gross margin
Gross margin is gross profit as a percentage of revenue.
TherapeuticsMD's gross margin for the twelve months ending Dec 31, 2023 was 100.0%. For fiscal 2023 it was 100.0%, against 98.0% the year before. The highest annual figure on record is 100.0% in fiscal 2023.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 100.0% | +2.0 |
| FY2022 | Dec 31, 2022 | 98.0% | +52.5 |
| FY2021 | Dec 31, 2021 | 45.5% | −29.9 |
| FY2020 | Dec 31, 2020 | 75.4% | −11.9 |
| FY2019 | Dec 31, 2019 | 87.2% | +4.2 |
| FY2018 | Dec 31, 2018 | 83.0% | −1.3 |
| FY2017 | Dec 31, 2017 | 84.3% | +5.9 |
| FY2016 | Dec 31, 2016 | 78.4% | +0.7 |
| FY2015 | Dec 31, 2015 | 77.6% | +2.1 |
| FY2014 | Dec 31, 2014 | 75.6% | −2.1 |
| FY2013 | Dec 31, 2013 | 77.7% | +13.0 |
| FY2012 | Dec 31, 2012 | 64.7% | +10.0 |
| FY2011 | Dec 31, 2011 | 54.6% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2023 | Dec 31, 2023 | 100.0% | +100.0 |
| Q2 FY2023 | Jun 30, 2023 | 100.0% | +100.0 |
| Q1 FY2023 | Mar 31, 2023 | 100.0% | −1982.4 |
| Q4 FY2022 | Dec 31, 2022 | 100.0% | +25.4 |
| Q3 FY2022 | Sep 30, 2022 | 0.0% | −79.2 |
| Q2 FY2022 | Jun 30, 2022 | 0.0% | −82.0 |
| Q1 FY2022 | Mar 31, 2022 | 2082.4% | +2006.0 |
| Q4 FY2021 | Dec 31, 2021 | 74.6% | −0.6 |
| Q3 FY2021 | Sep 30, 2021 | 79.2% | −3.8 |
| Q2 FY2021 | Jun 30, 2021 | 82.0% | +23.2 |
| Q1 FY2021 | Mar 31, 2021 | 76.4% | −1.4 |
| Q4 FY2020 | Dec 31, 2020 | 75.3% | −6.6 |
| Q3 FY2020 | Sep 30, 2020 | 83.0% | −10.9 |
| Q2 FY2020 | Jun 30, 2020 | 58.9% | −20.6 |
| Q1 FY2020 | Mar 31, 2020 | 77.8% | −2.8 |
| Q4 FY2019 | Dec 31, 2019 | 81.9% | +0.6 |
| Q3 FY2019 | Sep 30, 2019 | 93.9% | +14.0 |
| Q2 FY2019 | Jun 30, 2019 | 79.5% | −8.5 |
| Q1 FY2019 | Mar 31, 2019 | 80.7% | −2.5 |
| Q4 FY2018 | Dec 31, 2018 | 81.3% | −4.2 |
| Q3 FY2018 | Sep 30, 2018 | 79.9% | −4.3 |
| Q2 FY2018 | Jun 30, 2018 | 87.9% | +4.0 |
| Q1 FY2018 | Mar 31, 2018 | 83.2% | −0.3 |
| Q4 FY2017 | Dec 31, 2017 | 85.6% | +1.4 |
| Q3 FY2017 | Sep 30, 2017 | 84.1% | +6.5 |
| Q2 FY2017 | Jun 30, 2017 | 84.0% | – |
| Q1 FY2017 | Mar 31, 2017 | 83.5% | – |
| Q4 FY2016 | Dec 31, 2016 | 84.2% | – |
| Q3 FY2016 | Sep 30, 2016 | 77.6% | – |
See a number that looks wrong?